Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies
International Immunopharmacology · 2026-10 · 187 · 117134
DOI: 10.1016/j.intimp.2026.117134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-10. Verfasst von Raju Kumar Sarma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Guwahati, Kamrup, Assam 781125, India. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 158 Literaturangaben.
Abstract (Originalsprache)
Glioblastoma (GBM) is a lethal brain tumor with poor outcomes under standard therapies, and its rising global incidence underscores the urgent need for novel treatments. Chimeric antigen receptor T (CAR-T) cell therapy holds promise for GBM but faces unique challenges, including antigenic heterogeneity, a profoundly immunosuppressive tumor microenvironment (TME), limited trafficking across the blood brain barrier (BBB), and inadequate persistence. This comprehensive review provides an integrated perspective on emerging CAR-T strategies for GBM, systematically outlining ongoing and completed trials. It integrates innovative advances in multi-antigen targeting approaches such as bivalent, tandem, and multi-specific CAR constructs, as well as logic-gated designs that enhance tumor specificity and mitigate antigen escape. Further, we discuss advanced CAR engineering innovations such as armored cytokine-secreting constructs, metabolic reprogramming, and next-generation allogeneic platforms, including induced pluripotent stem cell (iPSC) derived CAR-T cell technologies aiming for durability, improvement and scalability. In parallel, novel delivery methods such as locoregional administration, nanoparticle/focused-ultrasound BBB modulation, and biomaterial scaffolds are also explored alongside rational combination approaches with checkpoint inhibitors and oncolytic virus. Collectively, this integrated perspective defines a translational roadmap for next generation CAR-T therapies, with the potential to achieve durable and clinically meaningful responses in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Guwahati, Kamrup, Assam 781125, India.
- Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Guwahati, Kamrup, Assam 781125, India. Electronic address: purbajit@ngiguwahati.in.
- Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology (IASST), Guwahati, Kamrup, Assam 781035, India.
Zitieren
APA
Sarma, R. K., Nath, P., Bora, P., Chetia, P., & Bala, A. (2026). Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies. International Immunopharmacology, 187, 117134. https://doi.org/10.1016/j.intimp.2026.117134
Vancouver
Sarma RK, Nath P, Bora P, Chetia P, Bala A. Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies. International Immunopharmacology. 2026;187:117134. doi:10.1016/j.intimp.2026.117134
BibTeX
@article{Sarma2026,
author = {Sarma, Raju Kumar and Nath, Parthajyoti and Bora, Paragmoni and Chetia, Purbajit and Bala, Asis},
title = {Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies},
journal = {International Immunopharmacology},
year = {2026},
volume = {187},
pages = {117134},
doi = {10.1016/j.intimp.2026.117134}
}
EUVIMED